Decavanadate Toxicology and Pharmacological Activities: V10or V1, Both or None?
This review covers recent advances in the understanding of decavanadate toxicology and pharmacological applications. Toxicologicalin vivostudies point out that V10induces several changes in several oxidative stress parameters, different from the ones observed for vanadate (V1). Inin vitrostudies with mitochondria, a particularly potent V10effect, in comparison with V1, was observed in the mitochondrial depolarization (IC50= 40 nM) and oxygen consumption (99 nM). It is suggested that mitochondrial membrane depolarization is a key event in decavanadate induction of necrotic cardiomyocytes death. Furthermore, only decavanadate species and not V1potently inhibited myosin ATPase activity stimulated by actin (IC50= 0.75μM) whereas exhibiting lower inhibition activities for Ca2+-ATPase activity (15 μM) and actin polymerization (17 μM). Because both calcium pump and actin decavanadate interactions lead to its stabilization, it is likely that V10interacts at specific locations with these proteins that protect against hydrolysis but, on the other hand, it may induce V10reduction to oxidovanadium(IV). Putting it all together, it is suggested that the pharmacological applications of V10species and compounds whose mechanism of action is still to be clarified might involve besides V10and V1also vanadium(IV) species.